Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen confirms safety of Alzheimer's drug

Actinogen confirms safety of Alzheimer's drug

Actinogen (ASX:ACW) has received confirmation from an independent Dose Escalation Committee that its lead drug candidate, Xanamem, when dosed at 10mg, satisfies safety, tolerability and pharmacokinetic metrics.

This now allows for a dose escalation to 25mg for the next cohort of 8 participants.

Actinogen expects the next cohort to be dosed in late March. The clinical trial program continues to execute on time and on budget.

Xanamem is being developed as a new therapy for Alzheimer’s disease, a condition with a multi-billion dollar market potential.

The cost of Alzheimer’s treatment in the US alone was estimated to be US$250 billion last year by the American Alzheimer’s Association.

This cost is estimated to increase to US$1 trillion by 2050, outstripping the cost of treating all other diseases.

Xanamem’s novel mechanism of action sets it apart from existing Alzheimer’s treatments.

It works by blocking the production of the stress hormone cortisol in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer’s disease.

There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer’s disease.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

cancer cells
February 11 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
Lab technician
August 07 2017
Avacta said it has developed multiple PD-L1 inhibitors, which are designed to use the body's own immune system to battle cancer
picture of doctor
September 06 2017
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use